Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.55 |
| ▸ | EP300 | Q09472 | 2/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 4/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409364 | 0.91 | MAPT (0.55) | MKNK1EP300CREBBPMAPTBAZ2B | |
| SCHEMBL406798 | 0.87 | MAPT (0.45) | MKNK1MAPTBAZ2BCFTR | |
| SCHEMBL18106974 | 0.86 | EP300 (0.43) | MKNK1EP300CREBBPBAZ2BCFTR | |
| SCHEMBL407207 | 0.86 | MAPT (0.49) | MKNK1MAPTCFTRTGFBR1P2RX3 | |
| SCHEMBL404753 | 0.79 | BAZ2B (0.48) | MKNK1MAPTBAZ2BCFTR | |
| SCHEMBL30667649 | 0.78 | MAPT (0.46) | MKNK1MAPTBAZ2BCFTRP2RX3 | |
| SCHEMBL18106971 | 0.78 | MAPT (0.42) | MKNK1EP300CREBBPMAPTBAZ2B | |
| SCHEMBL10139880 | 0.77 | MEN1 (0.56) | EP300CREBBPMAPTBAZ2B | |
| SCHEMBL30228575 | 0.76 | BAZ2B (0.74) | BAZ2BCFTRKDR | |
| SCHEMBL21114768 | 0.76 | BAZ2B (0.61) | MAPTBAZ2BCFTRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | claimed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | claimed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | claimed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | claimed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | claimed |
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022060-A1 | Tricyclic Azaindoles | AZI2, DCK, PPP2CA | MKNK1 54/4885EP300 473/4885CREBBP 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.